

January 13<sup>th</sup>, 2015  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer

**Completion of Patient Enrollment of rigosertib (SyB L-1101, IV)  
Phase I Trial in Patient with refractory or relapsed myelodysplastic syndrome (MDS)**

TOKYO, Japan, January 13<sup>th</sup>, 2014 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio") announced the completion of patient enrollment of Phase I clinical trial in Japan for rigosertib (SyB L-1101, IV) in patients with refractory or relapsed myelodysplastic syndrome (MDS)

MDS patients often require frequent blood transfusions due to the development of severe anemia (decrease in number of red blood cells), with a high rate of progression to acute myelogenous leukemia (AML). There are an estimated 11,000 MDS patients in Japan alone, the risk of MDS increases with age with treatment being more difficult in the elderly population. MDS and AML are blood disorders widely recognized as being difficult to manage with limited therapeutic options available for patients, especially those with drug-resistant disease and there is an urgent need to develop new therapies for the treatment of both relapsed/refractory (r/r) and frontline MDS.

**[Contact]**

Investor Relations

Tel: +81(0)3 5472 1125

**[Please read the following for more information on Onconova and Symbio]****About Onconova Therapeutics, Inc.**

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, the Company's most advanced product candidate, two other candidates are in clinical trials, and several candidates are in pre-clinical stages. For more information, please visit <http://www.onconova.com>.

**About Symbio Pharmaceuticals Limited**

Symbio Pharmaceuticals Ltd. was established in March, 2005, by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. The company's underlying corporate mission is "delivering hope to patients in need" as it aspires to be a leading specialty pharmaceutical company in Asia Pacific dedicated to addressing underserved medical needs with main focus in the areas of oncology, hematology and autoimmune disease.